{"id":52433,"date":"2023-08-24T09:11:43","date_gmt":"2023-08-24T13:11:43","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/which-is-a-better-buy-boston-scientific-stock-or-abbott\/"},"modified":"2023-08-24T09:11:45","modified_gmt":"2023-08-24T13:11:45","slug":"which-is-a-better-buy-boston-scientific-stock-or-abbott","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=52433","title":{"rendered":"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott?"},"content":{"rendered":"<div>\n<p>We believe <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/\">Boston Scientific stock <\/strong> (NYSE: BSX) will likely offer better returns over <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/\">Abbott stock<\/strong><strong> <\/strong>(NYSE: ABT) in the next three years. Boston Scientific<fbs-ticker data-name=\"BSX\" data-href=\"https:\/\/www.forbes.com\/companies\/boston-scientific\" data-type=\"stock\"><br \/>\n  BSX<br \/>\n <\/fbs-ticker> is trading at <strong>5.5x<\/strong> revenues compared to <strong>4.5x<\/strong> for Abbott. Investors have assigned a lower multiple to ABT due to a significant fall in its Diagnostics sales amid lower Covid-19 testing demand.<\/p>\n<p>Interestingly, BSX has had a Sharpe Ratio of <strong>0.5<\/strong> since early 2017, which is lower than <strong>0.6<\/strong> for the S&amp;P 500 Index over the same period. However, Abbott\u2019s Sharpe Ratio of <strong>0.7<\/strong> fared better than the S&amp;P500. This compares with the <strong>Sharpe of 1.3<\/strong> for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.<\/p>\n<p>If we look at stock returns, Boston Scientific, with 9% returns in the last twelve months, has fared better than Abbott, down 4%, and both have underperformed the broader S&amp;P 500 index, up 14%. There is more to the comparison, and in the sections below, we discuss why we believe BSX will offer better returns over ABT in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/1qC8UsGM\/Boston-Scientific-vs-Abbott-Laboratories-With-Return-Forecast-Of-18-Boston-Scientific-Is-A-Better-Bet?fromforbesandarticle=trefis230824\">Boston Scientific vs. Abbott<\/strong>: <strong>Which Stock Is A Better Bet?<\/strong> Parts of the analysis are summarized below.<\/p>\n<p><strong>1. Abbott\u2019s Revenue Growth Is Better<\/strong><\/p>\n<ul>\n<li>Abbott\u2019s revenue growth has been better, with an <strong>11.4%<\/strong> average annual growth rate in the last three years, compared to <strong>6.3%<\/strong> for Boston Scientific.<\/li>\n<li>A high demand for Covid-19 testing drove Abbott\u2019s sales growth in recent years. With the worst of Covid-19 behind us, the demand for testing has been declining, weighing on Abbott\u2019s diagnostics business in recent quarters.<\/li>\n<li>Abbott will see a dip in sales in 2023 owing to its diagnostics business. For perspective, Abbott expects total Covid-19-related sales of $2.0 billion in 2023, compared to $8.4 billion last year. However, it should return to growth next year, and its other businesses, including Medical Devices and Established Pharmaceuticals, should continue to grow steadily.<\/li>\n<li>For Boston Scientific, revenue growth is driven by an uptick in total procedures after a decline during the pandemic. It has also benefited from new product launches, including POLARx (Japan), Vercise, and XL valves.<\/li>\n<li>This trend is expected to continue going forward. Its recent acquisitions, including Baylis, will further bolster its top-line growth. The company has acquired a majority stake in Acotec, which will aid its future sales growth in China.<\/li>\n<li>Looking at the last twelve months, Boston Scientific\u2019s 8.7% sales growth has fared much better than -11.7% for Abbott.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/qIpcrHhU\/Boston-Scientific-BSX-Revenue-Comparison?fromforbesandarticle=trefis230824\">Boston Scientific Revenue Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/no-login-required\/IvrDgCeA\/Abbott-Laboratories-ABT-Revenue-Comparison?fromforbesandarticle=trefis230824\">Abbott Revenue Comparison<\/strong> dashboards provide more insight into the companies\u2019 sales.<\/li>\n<\/ul>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p><strong>2. Abbott Is More Profitable <\/strong><\/p>\n<ul>\n<li>Abbott\u2019s reported operating margin expanded from <strong>14%<\/strong> in 2019 to <strong>19% <\/strong>in 2022. In comparison, Boston Scientific\u2019s operating margin slid slightly from <strong>14%<\/strong> in 2019 to <strong>13%<\/strong> in 2022.<\/li>\n<li>Looking at the last twelve-month period, Abbott\u2019s operating margin of <strong>15% <\/strong>fares better than <strong>14% <\/strong>for Boston Scientific.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/VpAdgO3s\/Boston-Scientific-BSX-Operating-Income-Comparison?fromforbesandarticle=trefis230824\">Boston Scientific Operating Income Comparison<\/strong><strong> <\/strong>and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/no-login-required\/4Yi9Tgf4\/Abbott-Laboratories-ABT-Operating-Income-Comparison?fromforbesandarticle=trefis230824\">Abbott Operating Income Comparison<\/strong><strong> <\/strong>dashboards have more details.<\/li>\n<li>Looking at financial risk, Abbott fares better. Its <strong>9%<\/strong> debt as a percentage of equity is lower than <strong>12%<\/strong> for Boston Scientific Airlines, and its <strong>11%<\/strong> cash as a percentage of assets is higher than <strong>1%<\/strong> for the latter, implying that Abbott has a better debt position and has more cash cushion.<\/li>\n<\/ul>\n<p><strong>3. The Net of It All<\/strong><\/p>\n<ul>\n<li>We see that Abbott has seen superior revenue growth, is more profitable, has a better financial position, and is trading at a comparatively lower valuation multiple over Boston Scientific.<\/li>\n<li>Now, looking at prospects, using P\/S as a base, due to high fluctuations in P\/E and P\/EBIT, we believe Boston Scientific will offer better returns compared to Abbott over the next three years.<\/li>\n<li>Looking at recent financials, Abbott appears more appealing. Still, after a meaningful decline in the Covid-19 testing demand, the revenue growth for Abbott will likely be tepid. At the same time, Boston Scientific sales are expected to expand faster, aided by its new products.<\/li>\n<li>If we compare the current valuation multiples to the historical averages, ABT fares slightly better. Abbott stock trades at <strong>4.5x<\/strong> trailing sales compared to its last five-year average of <strong>5.4x<\/strong>, and Boston Scientific stock trades at <strong>5.5x<\/strong> vs. the last five-year average of <strong>5.9x<\/strong>.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/lkHGFK9g\/Boston-Scientific-BSX-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230824\">Boston Scientific Valuation Ratios Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/no-login-required\/9HfZn8bn\/Abbott-Laboratories-ABT-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230824\">Abbott Valuation Ratios Comparison<\/strong> have more details.<\/li>\n<li>The table below summarizes our revenue and return expectations for both companies over the next three years and points to an expected return of <strong>18%<\/strong> for Boston Scientific over this period vs. a <strong>9%<\/strong> expected return for Abbott stock, implying that investors will likely be better off picking BSX over ABT, based on Trefis Machine Learning analysis \u2013 <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/no-login-required\/1qC8UsGM\/Boston-Scientific-vs-Abbott-Laboratories-With-Return-Forecast-Of-18-Boston-Scientific-Is-A-Better-Bet?fromforbesandarticle=trefis230824\">Boston Scientific vs. Abbott<\/strong> \u2013 which also provides more details on how we arrive at these numbers.<\/li>\n<\/ul>\n<p>While BSX may outperform ABT in the next three years, it is helpful to see how <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BSX\/topic\/peer-comparisons\">Boston Scientific\u2019s Peers<\/strong> fare on metrics that matter. You will find other valuable comparisons for companies across industries at <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/topic\/peer-comparisons\">Peer Comparisons<\/strong><strong>.<\/strong><\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/08\/24\/which-is-a-better-buy--boston-scientific-stock-or-abbott\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific BSX is trading at 5.5x revenues compared to 4.5x for Abbott. Investors have assigned a lower multiple to ABT due to a significant fall in its Diagnostics sales amid lower Covid-19 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":52434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-52433","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=52433\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=52433\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-24T13:11:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T13:11:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/08\/1692882703_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=52433#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=52433\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott?\",\"datePublished\":\"2023-08-24T13:11:43+00:00\",\"dateModified\":\"2023-08-24T13:11:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=52433\"},\"wordCount\":862,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=52433#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=52433\",\"url\":\"https:\/\/ifintechworld.com\/?p=52433\",\"name\":\"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-08-24T13:11:43+00:00\",\"dateModified\":\"2023-08-24T13:11:45+00:00\",\"description\":\"We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=52433#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=52433\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=52433#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott? | iFintechWorld","description":"We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=52433","og_locale":"en_US","og_type":"article","og_title":"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott? | iFintechWorld","og_description":"We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific","og_url":"https:\/\/ifintechworld.com\/?p=52433","og_site_name":"iFintechWorld","article_published_time":"2023-08-24T13:11:43+00:00","article_modified_time":"2023-08-24T13:11:45+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/08\/1692882703_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=52433#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=52433"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott?","datePublished":"2023-08-24T13:11:43+00:00","dateModified":"2023-08-24T13:11:45+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=52433"},"wordCount":862,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=52433#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=52433","url":"https:\/\/ifintechworld.com\/?p=52433","name":"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-08-24T13:11:43+00:00","dateModified":"2023-08-24T13:11:45+00:00","description":"We believe Boston Scientific stock (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Boston Scientific","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=52433#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=52433"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=52433#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Which Is A Better Buy \u2013 Boston Scientific Stock Or Abbott?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/52433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52433"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/52433\/revisions"}],"predecessor-version":[{"id":52435,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/52433\/revisions\/52435"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/52434"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}